Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SLV337 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| A | EXPERIMENTAL | 400 mg suspension |
| B | ACTIVE_COMPARATOR | 5 x 200 mg immediate release capsule |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo |
| SLV337 | DRUG | SLV337 400 mg/day |
| SLV337 suspension | DRUG | 400 mg experimental |
| SLV337 capsule | DRUG | 5 x 200 mg immediate release capsule |
Inclusion Criteria Type 2 diabetes ,stable dose of Metformin,HbA1c \>= 7%, but \< 9% Exclusion Criteria Type 1 diabetes mellitus, Body Mass Index (BMI) \>40.0 kg/m2, evidence of unstable cardiovascular diseases, NYHA class I to IV, ALT \> 1.5 times UNL, creatinine clearance \<60 mL/min
Top 20 of 31 competitors
SLV337 is an investigational small molecule being studied for use in Type 2 Diabetes and in healthy subjects. It has been evaluated in clinical trials for these conditions, including a safety, pharmacokinetic, and pharmacodynamic study in patients with Type 2 Diabetes.
SLV337 is being developed by Abbott Laboratories, which trades under the ticker ABT. The company has sponsored clinical trials of the drug in patients with Type 2 Diabetes and in healthy subjects.
SLV337 is an investigational drug that has completed clinical trials. One trial was a Phase 1 study in healthy subjects, and another was a Phase 2 study in patients with Type 2 Diabetes. Both trials are completed, and the drug remains in clinical development.
SLV337 has been studied in two completed clinical trials. NCT00924534 was a Phase 2 safety, pharmacokinetic, and pharmacodynamic study in 61 patients with Type 2 Diabetes in Bulgaria, Poland, and South Africa. NCT01176201 was a Phase 1 ADME study in 12 healthy male subjects in the Netherlands.
SLV337 is the drug name used in its clinical trials. No alternative names for SLV337 have been identified in the available trial information.